Anthera Pharmaceuticals, Inc.
ANTH
ANTH was delisted on the 27th of June, 2018.
37 hedge funds and large institutions have $17.9M invested in Anthera Pharmaceuticals, Inc. in 2014 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 10 increasing their positions, 7 reducing their positions, and 6 closing their positions.
50% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 6
43% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 7
6% more funds holding
Funds holding: 35 → 37 (+2)
13% less capital invested
Capital invested by funds: $20.5M → $17.9M (-$2.59M)
83% less call options, than puts
Call options by funds: $8K | Put options by funds: $46K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
+$875K |
| 2 |
Franklin Resources
San Mateo,
California
|
+$715K |
| 3 |
GCM
Gruss Capital Management
New York
|
+$182K |
| 4 |
SIM
Spark Investment Management
New York
|
+$122K |
| 5 |
HighTower Advisors
Chicago,
Illinois
|
+$102K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$2.14M |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$476K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$192K |
| 4 |
JG
Jefferies Group
New York
|
-$192K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$153K |
ANTH Hedge Fund Activity: Q4 2014 in Review
37 of the 3,751 institutional investors tracked by Wall St. Rank reported a position in Anthera Pharmaceuticals, Inc. (ANTH) for Q4 2014, worth a combined $17.9M — down 13% from $20.5M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new ANTH positions and 6 closed out — a net gain of 3 holders — while 10 added to existing stakes and 7 trimmed.
The largest buyer was Broadfin Capital, adding an estimated $875K. The largest seller was Great Point Partners, cutting an estimated $2.14M.
- 37 institutional investors held Anthera Pharmaceuticals, Inc. (ANTH) as of Q4 2014, up from 35 in Q3 2014.
- Funds reported $17.9M of Anthera Pharmaceuticals, Inc. stock for Q4 2014, down 13% quarter-over-quarter.
- 9 funds opened new Anthera Pharmaceuticals, Inc. positions in Q4 2014 and 6 closed out, a net change of +3 holders.
- The largest Anthera Pharmaceuticals, Inc. buyer in Q4 2014 was Broadfin Capital, an estimated $875K added.
- The largest Anthera Pharmaceuticals, Inc. seller in Q4 2014 was Great Point Partners, an estimated $2.14M sold.
Based on aggregated 13F filings for Q4 2014.